Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunosuppression Intervention for ALS
NCT01884571Phase 2Completed
- Sponsor
- Emory University
- Start
- Oct 2013
- Primary completion
- Jan 2016
- Modality
- Monoclonal Antibodies, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of basiliximab, methylprednisolone injection, prednisone, tacrolimus + Wuzhi capsule, mycophenolate mofetil in amyotrophic lateral sclerosis (ALS), sponsored by Emory University. Started Oct 2013; status: completed.
02
Drugs
basiliximabmethylprednisolone injectionprednisonetacrolimus + Wuzhi capsulemycophenolate mofetil
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT01884571.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01884571.